

- Ross-Innes, C. S., Stark, R., Teschendorff, A. E., Holmes, K. A., Ali, H. R., Dunning, M. J., et al. (2012). Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. *Nature*, *481*, 389–393.
- Sagaert, X., De Paepe, P., Libbrecht, L., Vanhentenrijk, V., Verhoef, G., Thomas, J., et al. (2006). Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. *Journal of Clinical Oncology*, *24*, 2490–2497.
- Schuur, E. R., Loktev, A. V., Sharma, M., Sun, Z., Roth, R. A., & Weigel, R. J. (2001). Ligand-dependent interaction of estrogen receptor- α with members of the forkhead transcription factor family. *Journal of Biological Chemistry*, *276*, 33554–33560.
- Shigekawa, T., Ijichi, N., Ikeda, K., Horie-Inoue, K., Shimizu, C., Saji, S., et al. (2011). FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer. *Hormones & Cancer*, *2*, 286–297.
- Sørli, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proceedings of the National Academy of Sciences of the United States of America*, *98*, 10869–10874.
- Takayama, K., Horie-Inoue, K., Ikeda, K., Urano, T., Murakami, K., Hayashizaki, Y., et al. (2008). FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells. *Biochemical and Biophysical Research Communications*, *374*, 388–393.
- Tan, S. K., Lin, Z. H., Chang, C. W., Varang, V., Chng, K. R., Pan, Y. F., et al. (2011). AP-2 γ regulates oestrogen receptor-mediated long-range chromatin interaction and gene transcription. *EMBO Journal*, *30*, 2569–2581.
- Thorat, M. A., Marchio, C., Morimiya, A., Savage, K., Nakshatri, H., Reis-Filho, J. S., et al. (2008). Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. *Journal of Clinical Pathology*, *61*, 327–332.
- Wang, B., Lin, D., Li, C., & Tucker, P. (2003). Multiple domains define the expression and regulatory properties of Foxp1 forkhead transcriptional repressors. *Journal of Biological Chemistry*, *278*, 24259–24268.
- Wang, B., Weidenfeld, J., Lu, M. M., Maika, S., Kuziel, W. A., Morrissey, E. E., et al. (2004). Foxp1 regulates cardiac outflow tract, endocardial cushion morphogenesis and myocyte proliferation and maturation. *Development (Cambridge, England)*, *131*, 4477–4487.
- Wolf, I., Bose, S., Williamson, E. A., Miller, C. W., Karlan, B. Y., & Koeffler, H. P. (2007). FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. *International Journal of Cancer*, *120*, 1013–1022.
- Zhang, Y., Li, S., Yuan, L., Tian, Y., Weidenfeld, J., Yang, J., et al. (2010). Foxp1 coordinates cardiomyocyte proliferation through both cell-autonomous and nonautonomous mechanisms. *Genes & Development*, *24*, 1746–1757.

